• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用干扰素或干扰素诱导剂聚肌苷酸-聚胞苷酸调节5-氟尿嘧啶对小鼠的毒性作用。

Modulation of 5-fluorouracil-induced toxicity in mice with interferon or with the interferon inducer, polyinosinic-polycytidylic acid.

作者信息

Stolfi R L, Martin D S, Sawyer R C, Spiegelman S

出版信息

Cancer Res. 1983 Feb;43(2):561-6.

PMID:6184150
Abstract

Partially purified preparations of mouse interferon, administered during the 2-day period following the administration of a toxic dose of 5-fluorouracil (FUra), yielded significant protection from mortality in BALB/c X DBA/2 F1 mice. Protection against FUra-induced toxicity was also observed when the interferon inducer polyinosinic-polycytidylic acid (poly I X poly C) was administered with FUra. The temporal relationship between the administration of poly I X poly C and FUra was found to be a critical determinant of the intensity of toxic manifestations. In relation to FUra alone, poly I X poly C could enhance (when administered 48 hr before FUra), diminish (when administered together with FUra), or not affect (when administered 48 hr after FUra) the degree of resultant toxicity. Cytofluorometric analysis of the DNA content of bone marrow cells indicated a transient period (about 42 hr) of inhibition of cell cycling following the administration of poly I X poly C, followed by reentry into cycle (between 42 and 66 hr) and a return to normal cycle phase distribution by 90 hr. This disturbance of the kinetic pattern of cell cycling in bone marrow would explain the administration time-dependent variability of the effect of poly I X poly C on FUra toxicity, since FUra is known to be a cell cycle-specific cytotoxic drug. Potential practical application of this observation to the clinical use of FUra in cancer therapy is discussed.

摘要

在给予毒性剂量的5-氟尿嘧啶(FUra)后的2天内,给予部分纯化的小鼠干扰素制剂,可使BALB/c×DBA/2 F1小鼠的死亡率显著降低。当干扰素诱导剂聚肌苷酸-聚胞苷酸(poly I×poly C)与FUra一起给药时,也观察到对FUra诱导毒性的保护作用。发现poly I×poly C与FUra给药之间的时间关系是毒性表现强度的关键决定因素。与单独使用FUra相比,poly I×poly C可增强(在FUra给药前48小时给药时)、减弱(与FUra同时给药时)或不影响(在FUra给药后48小时给药时)最终毒性程度。对骨髓细胞DNA含量的细胞荧光分析表明,给予poly I×poly C后有一个短暂的细胞周期抑制期(约42小时),随后重新进入细胞周期(在42至66小时之间),并在90小时时恢复到正常的细胞周期阶段分布。骨髓细胞周期动力学模式的这种紊乱可以解释poly I×poly C对FUra毒性作用的给药时间依赖性变异性,因为已知FUra是一种细胞周期特异性细胞毒性药物。本文讨论了这一观察结果在FUra临床癌症治疗中的潜在实际应用。

相似文献

1
Modulation of 5-fluorouracil-induced toxicity in mice with interferon or with the interferon inducer, polyinosinic-polycytidylic acid.用干扰素或干扰素诱导剂聚肌苷酸-聚胞苷酸调节5-氟尿嘧啶对小鼠的毒性作用。
Cancer Res. 1983 Feb;43(2):561-6.
2
Modulation of chemotherapeutic drug activity with polyribonucleotides or with interferon.用多聚核糖核苷酸或干扰素调节化疗药物活性。
J Biol Response Mod. 1985 Dec;4(6):634-9.
3
Antagonistic effect of polyinosinic-polycytidylic acid on the cell lethality produced by 5-fluorouracil in human colon carcinoma cells in vitro.聚肌苷酸-聚胞苷酸对5-氟尿嘧啶在体外诱导人结肠癌细胞产生细胞致死性的拮抗作用。
Cancer Res. 1985 May;45(5):1953-7.
4
5-Fluorouracil incorporation into DNA of CF-1 mouse bone marrow cells as a possible mechanism of toxicity.
Cancer Res. 1984 Apr;44(4):1358-63.
5
Use of uridine rescue to enhance the antitumor selectivity of 5-fluorouracil.使用尿苷挽救来增强5-氟尿嘧啶的抗肿瘤选择性。
Cancer Res. 1983 Jul;43(7):3182-6.
6
Synergistic antitumor effect of fluoropyrimidines and polyinosinic-polycytidylic acid against L1210 leukemia.氟嘧啶与聚肌苷酸-聚胞苷酸联合对L1210白血病的协同抗肿瘤作用。
Cancer Res. 1985 Sep;45(9):4039-42.
7
Kinetic alterations induced by 5-fluorouracil in bone marrow, intestinal mucosa, and tumor.5-氟尿嘧啶对骨髓、肠黏膜及肿瘤所诱导的动力学改变。
Cancer Res. 1976 May;36(5):1653-8.
8
Effect of L-histidinol on the metabolism of 5-fluorouracil in the BALB/c x DBA/8 F1 murine tumor system.
Cancer Res. 1988 Dec 1;48(23):6664-8.
9
High-dose 5-fluorouracil with delayed uridine "rescue" in mice.小鼠中高剂量5-氟尿嘧啶联合延迟尿苷“解救”
Cancer Res. 1982 Oct;42(10):3964-70.
10
Modulation of 5-fluorouracil host-toxicity and chemotherapeutic efficacy against human colon tumors by 5-(Phenylthio)acyclouridine, a uridine phosphorylase inhibitor.尿苷磷酸化酶抑制剂5-(苯硫基)阿糖脲苷对5-氟尿嘧啶宿主毒性及抗人结肠肿瘤化疗疗效的调节作用
Cancer Chemother Pharmacol. 2006 Nov;58(5):692-8. doi: 10.1007/s00280-006-0213-x. Epub 2006 Mar 10.

引用本文的文献

1
A randomized controlled trial to evaluate the role of interferon as initial and maintenance therapy in patients with follicular lymphoma.一项评估干扰素作为滤泡性淋巴瘤患者初始及维持治疗作用的随机对照试验。
Br J Cancer. 2001 Jul 6;85(1):29-35. doi: 10.1054/bjoc.2001.1822.
2
Pharmacokinetic interaction of 5-fluorouracil and interferon alpha-2b with or without folinic acid.
Med Oncol. 1995 Mar;12(1):47-53. doi: 10.1007/BF01571408.
3
Double modulation of 5-fluorouracil by high-dose leucovorin and interferon alpha 2b in advanced colorectal cancer: a phase I and a phase II study of weekly administration.高剂量亚叶酸钙和干扰素α-2b对晚期结直肠癌患者5-氟尿嘧啶的双重调节作用:每周给药的I期和II期研究
J Cancer Res Clin Oncol. 1994;120(5):314-8. doi: 10.1007/BF01236390.
4
Effective treatment of liver metastases from colon cancer with a combination of gamma-interferon and cisplatin chemotherapy: report of a case.γ-干扰素联合顺铂化疗有效治疗结肠癌肝转移:病例报告
Surg Today. 1995;25(4):357-60. doi: 10.1007/BF00311260.
5
New targets for pyrimidine antimetabolites in the treatment of solid tumours. 1: Thymidylate synthase.嘧啶抗代谢物在实体瘤治疗中的新靶点。1:胸苷酸合成酶。
Pharm World Sci. 1994 Apr 15;16(2):84-103. doi: 10.1007/BF01880660.
6
Combined effect of 5-fluorouracil and interferon on experimental liver metastases of rat colon carcinoma.5-氟尿嘧啶与干扰素联合对大鼠结肠癌实验性肝转移的作用
J Cancer Res Clin Oncol. 1985;109(2):156-8. doi: 10.1007/BF00391891.
7
Drug treatment of colorectal cancer. Current status.结直肠癌的药物治疗。现状。
Drugs. 1991 Oct;42(4):616-27. doi: 10.2165/00003495-199142040-00005.
8
A phase II trial of interferon alpha-2A plus fluorouracil in advanced renal cell carcinoma. A Hoosier Oncology Group study.干扰素α-2A联合氟尿嘧啶用于晚期肾细胞癌的II期试验。一项印第安纳肿瘤学组的研究。
Invest New Drugs. 1992 Aug;10(3):225-30. doi: 10.1007/BF00877251.